IL12RB2 and lung adenocarcinoma: In principle, IL-12 might be administered to lung adenocarcinoma patients (selected on the ground of IL-12Rβ2 expression in tumor cells) as tumor-targeted formulations to act directly on the tumor microenvironment [39] or systemically to take advantage of the immunomodulatory activity of the cytokine [3].